The past decade has witnessed a new surge in the development of complement-targeted therapeutics, fueled by the successful launch of first complement drugs and the discovery of both orphan and highly prevalent diseases with contribution of complement. Apart from offering new hope for patients suffering from such diseases, the study of complement pathways, mutations, and deficiencies also teaches us important lessons about the role of complement in health and disease and allows us to refine our models and tools for applied and basic research. This book, which follows the Aegean Conference on Complement Therapeutics in June 2011, brings together academic and industry scientists and clinical development experts who are focused on contemporary and emerging aspects of complement-mediated disease pathogenesis and the development of therapeutics that modulate this system in a beneficial manner. Topics covered here include targets, mechanisms & delivery options; therapeutic approaches & pipeline compounds; infections, periodontal diseases & sepsis; autoimmune & blood disorders (e.g. lupus, PNH); inflammatory diseases (e.g. asthma, arthritis); ocular diseases (e.g. AMD); kidney diseases (e.g. aHUS, MPGN II); neurological diseases (e.g. Alzheimer's); metabolic & cardiovascular diseases; organ/cell transplantation & I/R injury; biomaterials & drug delivery devices; diagnostics & imaging.